655. Multiple Myeloma: Cellular Therapies: Poster I

Trial in progress QUINTESSENTIAL 2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma RRMM exposed to lenalidomide

Prospective study of fluoroquinolone resistance colonization in patients undergoing autologous hematopoietic stem cell transplantation in the treatment of multiple myeloma

Promising safety and efficacy of equecabtagene autoleucel eque cel  followed ASCT in ultra high risk multiple Myeloma  UHR MM patients primary real world data from a single center

Safety and efficacy of autologous hematopoietic stem cell transplantation followed by CAR T therapy in patients with high risk or advanced plasma cell neoplasms

KarMMa 3 subgroup analysis in older patients with relapsed refractory multiple myeloma treated with idecabtagene vicleucel

A first in human study of CT0596 an allogeneic CAR T cell therapy targeting BCMA in patients with relapsed refractory multiple myeloma

Phase I study of NPB5005 V283 in patients with relapsed refractory multiple myeloma

Multi omic analysis reveals metabolic fitness of the ARI0002h BCMA CAR T cell infusion product as a key predictor of clinical outcomes in multiple myeloma

Functionally high risk disease is associated with inferior outcomes after chimeric antigen receptor T cell therapy for relapsed refractory multiple myeloma

Prolonged cytopenias after BCMA CAR‑T are associated with impaired endogenous T cell recovery characterized by decreased CD8 T cell diversity